GlassScriptPhysician profile
Steven Alexander Gabriel
NPI 1407860919
$3,198.54
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $1,087 · 2021: $1,142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $760.22 | 2019-2021 | |
| Novo Nordisk INC | $475.04 | 2019-2021 | |
| Pfizer INC. | $423.86 | 2019-2021 | |
| Amarin Pharma, INC. | $393.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $288.52 | 2019-2021 | |
| Lilly USA, LLC | $176.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.87 | 2019-2021 | |
| Amgen INC. | $146.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $128.87 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $67.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $50.42 | 2019-2021 | |
| Esperion Therapeutics, INC. | $37.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $28.90 | 2019-2021 | |
| Amryt Pharma Holdings LTD | $17.08 | 2021 | |
| Abbvie INC. | $14.28 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.62 | 2021 | |
| Biodelivery Sciences International, INC. | $13.43 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.